The Buyback Machine Hiding Behind Cardinal Health’s Thin Margins

A steadily shrinking share count and a giant float owed to suppliers are handing owners a bigger slice of the drug distributor each year, even as drug-pricing worries hang over the stock.

Cardinal Health (CAH) stock has quietly gained about 46% over the past year and now trades roughly 5% below its 52-week high, yet the number that should catch an owner’s eye is not the price. Over the past three years the company’s earnings per share have compounded about 71% a year, faster than the roughly 62% annual growth in net income beneath them. That gap is no accounting quirk. It is partly what happens when a company keeps buying back its own stock: the profit is split across fewer and fewer shares, so each one you hold lays claim to a growing slice of the business.

How A Shrinking Share Count Grows Your Stake

Cardinal Health spent about $1 billion buying back shares over the past twelve months and paid roughly $491 million in dividends on top of that, a combined shareholder yield near 1.9% of its market value once shares issued to employees are netted out. The buyback did the heavy lifting: the share count fell about 2.1% over the past year and has come down around 2.8% a year over the past three. Do nothing and sell nothing, and your ownership of the company still grows a little every year. That steady retirement is one reason the stock has returned about 155% over three years, or roughly 37% annualized, against 68% for the S&P 500, though buybacks are only one driver alongside earnings growth and a rising valuation.

The Supplier Float That Pays For It

Here is the part that does not fit the usual picture of a cash-rich compounder. Cardinal Health earns an operating margin of just about 1.2%, wafer-thin even for a drug distributor. What it lacks in margin it makes up in float. The company carries around $37.8 billion in accounts payable, roughly 2.1 times the value of its inventory, which means it collects cash from customers well before it has to pay its suppliers. That negative working-capital cycle is why operating cash flow runs about 3.2 times reported net income, throwing off far more cash than the thin margin alone would suggest. It is that cash, not fat profits, that funds the dividend and the buyback.

Can The Engine Survive The Drug-Pricing Squeeze?

The worry the market keeps circling is drug-price reform. New pricing adjustments tied to the Inflation Reduction Act have weighed on reported pharmaceutical revenue growth, and the company took a $184 million goodwill impairment on its Navista oncology business after raising the risk assumptions behind it. Management argues its distribution fees are contracted and protected regardless of where drug prices land, and the top line still grew about 12.8% over the trailing twelve months, helped by specialty medicines growing more than 20%. On the durability of the payout itself, the math is reassuring: free cash flow covers the buybacks and dividends about 2.9 times over, net debt sits near 1.5 times EBITDA, and operating earnings cover interest roughly 6.8 times, comfortable coverage for one of the larger names in the health care sector.

Is A Thin-Margin Compounder Worth Paying Up For?

So where does that leave you? The stock is not cheap: it trades at about 34.5 times trailing earnings, a rich multiple for a distributor and a genuine risk if growth cools or sentiment sours, because a compounder can still de-rate no matter how many shares it retires. But the engine underneath is doing exactly what it should. Earnings are outrunning the business, the cash to keep shrinking the share count is real and well-covered, and the full valuation is riding a genuine acceleration rather than hope. If you want to judge whether the price already banks all of that, our expected-move screen shows how much movement the options market is pricing in before its next earnings update. The honest read is a solid compounder priced for continued execution, with drug-pricing policy the swing factor to watch.

Even A Cash Machine This Steady Is One Position

None of this makes Cardinal Health a sure thing. A single stock, however smoothly its buyback engine runs, still carries the full weight of one company’s exposure to drug-pricing rules and one industry’s cycle. A rules-based portfolio spreads that risk across names picked and re-balanced by a system rather than by conviction, so no single wager can sink it. Our High Quality portfolio is built exactly that way, aiming to compound steadily through the noise. If the discipline behind Cardinal Health’s share retirement is what appeals to you, that same discipline spread across a whole basket is what a portfolio delivers at scale. It has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000.